Research programme: Rel protein inhibitors - BioLineRx/Hebrew University of Jerusalem

Drug Profile

Research programme: Rel protein inhibitors - BioLineRx/Hebrew University of Jerusalem

Alternative Names: EDP 25

Latest Information Update: 27 Sep 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hebrew University of Jerusalem
  • Developer BioLineRx; Hebrew University of Jerusalem
  • Class
  • Mechanism of Action Bacterial protein inhibitors; Proto-oncogene protein c-rel inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Bacterial infections

Most Recent Events

  • 27 Sep 2013 Early research is ongoing in Israel
  • 28 Sep 2011 Early research in Bacterial infections in Israel (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top